NCT06717165 Efficacy and Mechanism of Augmentation of Cognitive Behavioral Therapy With Transcranial Alternating Current Stimulation(tACS) for Obsessive-Compulsive Disorder (OCD)
| NCT ID | NCT06717165 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Mental Health Center |
| Condition | Obsessive Compulsive Disorder (OCD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 62 participants |
| Start Date | 2024-04-15 |
| Primary Completion | 2027-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 62 participants in total. It began in 2024-04-15 with a primary completion date of 2027-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the feasibility and clinical outcome of the Exposure-based Cognitive-Behavioral Therapy (CBT) concurrent with Transcranial Alternating Current Stimulation (tACS) using individualized stimulation frequency in treating obsessive-compulsive disorder (OCD) patients, and explores the potential neural mechanisms of treatment effect by magnetic resonance imaging (MRI) and electroencephalography (EEG).
Eligibility Criteria
The investigators recruited outpatient adults with OCD confirmed by the Mini-International Neuropsychiatric Interview (MINI). The following inclusion and exclusion criteria were also applied: Inclusion Criteria: * 18-60 years old * With at least 9 years of education * Y-BOCS score ≥16 * No history of serious medical, neurological illness or other psychotic disorders other than OCD (anxiety or mild to moderate depression secondary to OCD was not exclusionary) * Medication-free or had received stable medication for at least 8 weeks before entering the study and continued the same medication throughout the study Exclusion Criteria: * History of serious medical, neurological illness or other psychotic disorders other than OCD * OCD symptoms are severe, preventing the patient from completing the required assessment and examination * Serious suicide risk * Women who are pregnant or planning to become pregnant * Currently taking antiepileptic medication * Clinically significant physical illnesses or laboratory test abnormalities that have clinical significance * Previous completion of a full course of CBT/ERP treatment
Contact & Investigator
Zhen Wang, PhD, MD
PRINCIPAL INVESTIGATOR
Shanghai Mental Health Center
Frequently Asked Questions
Who can join the NCT06717165 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Obsessive Compulsive Disorder (OCD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06717165 currently recruiting?
Yes, NCT06717165 is actively recruiting participants. Contact the research team at wangzhen@smhc.org.cn for enrollment information.
Where is the NCT06717165 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06717165 clinical trial?
NCT06717165 is sponsored by Shanghai Mental Health Center. The principal investigator is Zhen Wang, PhD, MD at Shanghai Mental Health Center. The trial plans to enroll 62 participants.